CN106822988B - 海藻纤维功能性敷料及其应用、海藻纤维功能性敷料贴 - Google Patents
海藻纤维功能性敷料及其应用、海藻纤维功能性敷料贴 Download PDFInfo
- Publication number
- CN106822988B CN106822988B CN201710066389.3A CN201710066389A CN106822988B CN 106822988 B CN106822988 B CN 106822988B CN 201710066389 A CN201710066389 A CN 201710066389A CN 106822988 B CN106822988 B CN 106822988B
- Authority
- CN
- China
- Prior art keywords
- skin
- dressing
- fiber functional
- alginate fiber
- functional dressing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000835 fiber Substances 0.000 title claims abstract description 100
- 229940072056 alginate Drugs 0.000 title claims abstract description 82
- 235000010443 alginic acid Nutrition 0.000 title claims abstract description 82
- 229920000615 alginic acid Polymers 0.000 title claims abstract description 82
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 title claims abstract description 76
- 239000002994 raw material Substances 0.000 claims abstract description 31
- 239000000853 adhesive Substances 0.000 claims abstract description 22
- 230000001070 adhesive effect Effects 0.000 claims abstract description 22
- 230000035876 healing Effects 0.000 claims abstract description 22
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 20
- 239000002344 surface layer Substances 0.000 claims abstract description 19
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 21
- 239000003242 anti bacterial agent Substances 0.000 claims description 18
- 239000000463 material Substances 0.000 claims description 15
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 12
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 9
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 9
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 9
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- IJVRPNIWWODHHA-UHFFFAOYSA-N 2-cyanoprop-2-enoic acid Chemical compound OC(=O)C(=C)C#N IJVRPNIWWODHHA-UHFFFAOYSA-N 0.000 claims description 7
- 239000004744 fabric Substances 0.000 claims description 7
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 6
- 238000002324 minimally invasive surgery Methods 0.000 claims description 6
- 239000001509 sodium citrate Substances 0.000 claims description 6
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 6
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical group OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 5
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims description 5
- 239000002657 fibrous material Substances 0.000 claims description 5
- 239000004745 nonwoven fabric Substances 0.000 claims description 5
- 239000001814 pectin Substances 0.000 claims description 4
- 235000010987 pectin Nutrition 0.000 claims description 4
- 229920001277 pectin Polymers 0.000 claims description 4
- 239000001488 sodium phosphate Substances 0.000 claims description 4
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 4
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 4
- 229920000742 Cotton Polymers 0.000 claims description 3
- 231100000444 skin lesion Toxicity 0.000 claims 1
- 206010040882 skin lesion Diseases 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 abstract description 42
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract description 30
- 239000000679 carrageenan Substances 0.000 abstract description 30
- 235000010418 carrageenan Nutrition 0.000 abstract description 30
- 229920001525 carrageenan Polymers 0.000 abstract description 30
- 229940113118 carrageenan Drugs 0.000 abstract description 30
- -1 carrageenan oligosaccharide Chemical class 0.000 abstract description 30
- 241001474374 Blennius Species 0.000 abstract description 28
- 150000008442 polyphenolic compounds Chemical class 0.000 abstract description 18
- 235000013824 polyphenols Nutrition 0.000 abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 17
- 239000011780 sodium chloride Substances 0.000 abstract description 15
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 abstract description 13
- 229920002125 Sokalan® Polymers 0.000 abstract description 13
- 229960001631 carbomer Drugs 0.000 abstract description 13
- 230000029663 wound healing Effects 0.000 abstract description 13
- 150000002482 oligosaccharides Chemical class 0.000 abstract description 12
- 230000008439 repair process Effects 0.000 abstract description 10
- 239000008215 water for injection Substances 0.000 abstract description 10
- 241000199919 Phaeophyceae Species 0.000 abstract description 7
- 208000028990 Skin injury Diseases 0.000 abstract description 7
- 239000012567 medical material Substances 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 102
- 208000027418 Wounds and injury Diseases 0.000 description 47
- 206010052428 Wound Diseases 0.000 description 45
- 230000000694 effects Effects 0.000 description 20
- 201000004624 Dermatitis Diseases 0.000 description 19
- 208000010668 atopic eczema Diseases 0.000 description 18
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 12
- 230000008901 benefit Effects 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 206010012434 Dermatitis allergic Diseases 0.000 description 10
- 201000008937 atopic dermatitis Diseases 0.000 description 10
- 150000003254 radicals Chemical class 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 208000002874 Acne Vulgaris Diseases 0.000 description 8
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 8
- 206010000496 acne Diseases 0.000 description 8
- 235000010350 erythorbic acid Nutrition 0.000 description 8
- 230000001815 facial effect Effects 0.000 description 8
- 229940026239 isoascorbic acid Drugs 0.000 description 8
- 230000000474 nursing effect Effects 0.000 description 8
- 230000033228 biological regulation Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 230000003020 moisturizing effect Effects 0.000 description 6
- 231100000241 scar Toxicity 0.000 description 6
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 6
- 208000035143 Bacterial infection Diseases 0.000 description 5
- 206010039509 Scab Diseases 0.000 description 5
- 208000022362 bacterial infectious disease Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 239000011505 plaster Substances 0.000 description 5
- 230000002980 postoperative effect Effects 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 208000032544 Cicatrix Diseases 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 206010041303 Solar dermatitis Diseases 0.000 description 3
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 231100000899 acute systemic toxicity Toxicity 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000037387 scars Effects 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 206010012435 Dermatitis and eczema Diseases 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical group CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 206010072170 Skin wound Diseases 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 239000011176 biofiber Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000004318 erythorbic acid Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 239000013081 microcrystal Substances 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 229920002414 procyanidin Polymers 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000018040 scab formation Effects 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- 235000002837 Acetobacter xylinum Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241001136169 Komagataeibacter xylinus Species 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- 241000195474 Sargassum Species 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000037313 granulation tissue formation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 238000002430 laser surgery Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 239000006254 rheological additive Substances 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/24—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/58—Adhesives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0014—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/106—Halogens or compounds thereof, e.g. iodine, chlorite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了一种海藻纤维功能性敷料及其应用、海藻纤维功能性敷料贴,涉及医用材料领域。该海藻纤维功能性敷料的原料按质量百分数计包括:卡拉胶寡糖0.5~2%、褐藻寡糖1.5~3%、海藻多酚0.5~1.5%、原花青素0.5~2.5%、氯化钠0.05~0.2%、卡波姆0.5~1.5%;PH调节剂0.01~0.1%、皮肤粘合剂0.5~2%、润肤保湿剂0.01~0.2%、余量为注射用水。海藻纤维功能性敷料贴包括吸附有上述海藻纤维功能性敷料的敷料面层。海藻纤维功能性敷料能有效修复和愈合皮肤损伤,缩短了伤口愈合的时间。此外,本发明提供了上述海藻纤维功能性敷料在修复和愈合皮肤损伤中的应用。
Description
技术领域
本发明涉及医用材料领域,具体而言,涉及一种海藻纤维功能性敷料及其应用、海藻纤维功能性敷料贴。
背景技术
20世纪50年代以后的有关研究发现:伤口上的水疱完整的伤口比水疱破溃的伤口愈合速度明显加快。1962年英国G.D.WinterHinman博士的动物实验发现,湿性环境的伤口愈合速度比干性愈合快1倍,Winter博士首次证实了湿润且具有通透性的伤口敷料应用所形成的湿性环境中,表皮细胞能更好地繁衍和移行,这一研究结果和湿性环境愈合理论发表在《Nature》。1963Hinman首次在人的伤口处理中得出同样的结论。1990年Turner证实湿润环境能迅速缩小创面,增加肉芽组织形成,促进创面再上皮化。美国约翰·霍普金斯大学Fonder等的报告指出以干燥的方式促使伤口愈合一直是伤口处理得一个误区。在过去的40年多年中,大量的研究报告证明,湿性愈合理论已被欧美国家医疗界所接受。
20世纪60年代前沿用了半个多世纪的伤口敷料其设计理念均是吸收渗液和创面隔离的作用。对敷料材质的研究也主要是从生物惰性、无毒性和生物相容性等方面来考虑的,传统的干燥疗法虽可减少创面感染的机会,但失去了正常功能的创面,直接暴露于干燥的空气或吸湿性很强的敷料包扎下,创面大量的水分蒸发或丢失,将会使瘀滞带细胞大量失水,又因充血水肿带微循环障碍,水分不能及时得到补充,受损组织因脱水而加速死亡,使得创面加深,影响创面愈合的吸收性有限,湿性愈合环境可以改善微循环,减少组织细胞坏死,最大限度的保护创面有生机的组织细胞,使濒临死亡的细胞逐渐恢复正常,同时为充血水肿的细胞带的早期恢复创造条件。
2000年8月,美国食品与药品管理局(FDA)在新颁布的行业指南中指出:保持伤口的湿润环境是标准的伤口处理方法。运用湿性愈合理论治疗创伤面能减轻疼痛和避免干痂形成,并形成湿润的愈合环境。大大缩短了伤口愈合的时间,降低了伤口污染和感染的发生,减少了护理人员工作量,显著提高了临床经济效益。
医学整形美容逐步发展,例如面部激光、光子嫩肤、微晶磨削、果酸活肤术等,这些微创手术后需要对创面肌肤进行护理,而现有的敷料仍然采用干燥疗法,干燥疗法易加深创面,同时易形成干痂。
发明内容
本发明的目的在于提供一种海藻纤维功能性敷料,其能有效修复和愈合皮肤损伤,缩短了伤口愈合的时间,降低了伤口污染和感染的发生,降低疤痕的产生。
本发明的另一目的在于提供一种具有上述海藻纤维功能性敷料的海藻纤维功能性敷料贴。
本发明的又一目的在于提供上述海藻纤维功能性敷料在修复和愈合皮肤损伤中的应用。
本发明解决其技术问题是采用以下技术方案来实现的。
一种海藻纤维功能性敷料,其原料按质量百分数计包括:
优选的,在本发明的较佳实施例中,上述海藻纤维功能性敷料的原料按质量百分数计包括:
优选的,在本发明的较佳实施例中,上述海藻纤维功能性敷料的PH调节剂包括柠檬酸、磷酸、磷酸钠和柠檬酸钠中的至少一种。
优选的,在本发明的较佳实施例中,上述海藻纤维功能性敷料的皮肤粘合剂包括羧甲基纤维素钠和α-氰基丙烯酸酯中的至少一种
优选的,在本发明的较佳实施例中,上述海藻纤维功能性敷料的润肤保湿剂为三乙醇胺或丙三醇。
优选的,在本发明的较佳实施例中,上述海藻纤维功能性敷料的原料按质量百分数计还包括抗菌剂0.04~0.2%,抗菌剂包括生物肽、壳寡糖和十三肽中的至少一种。
优选的,在本发明的较佳实施例中,上述海藻纤维功能性敷料的原料按质量百分数计还包括异抗坏血酸0.2~0.3%。
一种海藻纤维功能性敷料贴,其包括敷料面层,敷料面层上均匀吸附有上述海藻纤维功能性敷料。
优选的,在本发明的较佳实施例中,上述海藻纤维功能性敷料贴的敷料面层的材料选自无纺布、生物纤维材料、果胶纤维布、棉布和蚕丝中的任意一种。
上述海藻纤维功能性敷料在修复和愈合皮肤损伤中的应用。
与现有技术相比,本发明的有益效果是:该海藻纤维功能性敷料的原料中的卡拉胶寡糖还具有抗凝血作用,能够帮助受损肌肤的伤口愈合,同时卡拉胶寡糖对辐射损伤有明显的防护作用,并且具有很强的清除超氧阴离子自由基以及羟自由基的活性,并且具有还原能力,而褐藻寡糖、海藻多酚和原花青素都具有抗氧化活性,卡拉胶寡糖与褐藻寡糖、海藻多酚和原花青素相互配合,加强了抗氧化活性的能力,进而能够对受损皮肤起到修护作用,此外,褐藻寡糖、海藻多酚、原花青素和氯化钠还具有抑菌活性,能够防止受损肌肤受到细菌及真菌的损害,保护受损肌肤,此外,原料中的PH调节剂能够调节海藻纤维功能性敷料和皮肤的pH值,使肌肤保持最佳状态,而皮肤粘合剂能够帮助受损肌肤伤口愈合,润肤保湿剂能够保持肌肤水分,进而保持伤口的湿润环境。卡波姆能够将上述原料凝胶和增稠,便于海藻敷料与敷料面层贴合。运用湿性愈合理论治疗创伤面能减轻疼痛和避免干痂形成,并形成湿润的愈合环境。大大缩短了伤口愈合的时间,降低了伤口污染和感染的发生,减少了护理人员工作量,显著提高了临床经济效益。本发明实施例中选用的原料均为安全无毒副作用的材料,更安全。将敷料面层浸泡于上述海藻纤维功能性敷料中,然后将敷料面层直接作用于受损肌肤,能够对受损肌肤起到修复和愈合的作用。本发明运用湿性愈合理论治疗创伤面能减轻疼痛和避免干痂形成,并形成湿润的愈合环境。大大缩短了伤口愈合的时间,降低了伤口污染和感染的发生,减少了护理人员工作量,显著提高了临床经济效益。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚,下面将对本发明实施例中的技术方案进行清楚、完整地描述。实施例中未注明具体条件者,按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者,均为可以通过市售购买获得的常规产品。
下面对本发明实施例的一种海藻纤维功能性敷料及其应用、一种海藻纤维功能性敷料贴进行具体说明。
一种海藻纤维功能性敷料,其原料按质量百分数计包括:
优选地,上述原料按质量百分比计包括:
下面对上述原料的具体成分进行阐述:
卡拉胶寡糖主要由卡拉胶降解得到,相对卡拉胶而言,卡拉胶寡糖分子量较小、溶解性较好、稳定性和安全性都有所改善,同时因分子链上的活性基团充分暴露,其原有的活性得到提高,甚至产生了新的活性。
卡拉胶寡糖能够明显减轻辐射引起的脾脏NK细胞活性的降低,造血功能受抑制、血细胞来源减少等症状,提高机体免疫功能,对辐射损伤有明显的防护作用。
卡拉胶寡糖主要通过增强辐射损伤机体免疫器官的保护和造血功能恢复两方面发挥抗辐射作用。同时卡拉寡糖具有很强的清除超氧阴离子自由基以及羟自由基的活性,并且具有还原能力。卡拉胶寡糖还具有细胞内抗氧化活性,它能保护细胞免受过氧化氢的损伤。此外,卡拉胶寡糖还具有抗凝血作用:卡拉胶具有与肝素相似的抗凝血活性,未降解的卡拉胶和纤维蛋白形成不溶性复合物,而降解的卡拉胶寡糖与血纤维蛋白生成可溶性复合物,且其毒性比未降解卡拉胶明显减小。
褐藻寡糖具有抗炎症、调节机体免疫活性、促进细胞生长和抗自由基氧化的作用,是纯天然海洋生物制剂。海藻多酚具有抗氧化活性和抑菌活性。
原花青素能够消除术后皮肤创伤带来的水肿,原花青素不仅帮助胶原蛋白纤维形成交联结构,而且可以帮助恢复因受伤和自由基所引起的过度交联的损害。花青素还保护人体免受阳光伤害,促进治愈牛皮癣和寿斑。原花青素在护肤品中起到多重作用,如抗衰老、抗紫外线、抗辐射、增白、保湿等,对多种因素造成的皮肤老化都有独特的功效。
氯化钠浓度高于人的生理浓度,可以通过渗透压杀死细菌以及真菌。寄生在人体皮肤创伤表面的细菌,其细胞质浓度与人体生理浓度相当,氯化钠浓度高于细菌细胞质浓度,可用于杀死细菌。此外,氯化钠能够增大化妆品配方体系的粘度作用,可以减少配方原料应用量,降低成本。
卡波姆是一类非常重要的流变调节剂,中和后的卡波姆是优秀的凝胶基质,有增稠、悬浮等重要用途,稳定性好,广泛应用于乳液、膏霜、凝胶中。卡波姆的添加能够将上述原料凝胶、增稠,使海藻纤维功能性敷料与皮肤或敷料面层贴合。
PH调节剂用于调节该海藻纤维功能性敷料的PH以及肌肤PH,使肌肤处于最佳修复状态。PH调节剂包括柠檬酸、磷酸、磷酸钠和柠檬酸钠中的至少一种。
皮肤粘合剂用于粘合受损皮肤,帮助皮肤愈合,本实施例中,皮肤粘合剂选自羧甲基纤维素钠和α-氰基丙烯酸酯中的至少一种。羧甲基纤维素钠能够作为增稠剂,同时作为药物载体,在粘合受损皮肤时,将海藻纤维功能性敷料的有效成分渗入肌肤,帮助受损肌肤修复和愈合。而α-氰基丙烯酸酯不仅仅能够粘合受损肌肤,还具有一定的抗菌作用,避免术后缝线排斥反应。因而在皮肤挫裂伤处理方面具有感染率低,术后瘢痕小等优点。
润肤保湿剂能够对受损皮肤起到保湿和润滑的作用,在修复肌肤的同时,保持肌肤水分。本实施例中润肤保湿剂为三乙醇胺或丙三醇。
此外,原料按质量百分数计还包括抗菌剂0.04~0.2%和异抗坏血酸0.2~0.3%。具体地,抗菌剂能够有效防止受损皮肤受到细菌和真菌的感染。抗菌剂包括生物肽、壳寡糖和十三肽中的至少一种。异抗坏血酸的抗氧化能力远远超过维生素C,人体摄取异抗坏血酸,在体内可转变成维生素C,进而对人体肌肤具有美白功效。异抗坏血酸的加入能够提高海藻纤维功能性敷料的抗氧化能力,从而使海藻纤维功能性敷料能够适用于日光性皮炎,并且对过度晒伤所导致的皮肤损伤有明显的改善和修复作用,从而能够淡斑、祛斑。
承上述,卡拉胶寡糖、褐藻寡糖和海藻多酚能够抗自由基氧化、抗炎症、提高角质细胞生长;褐藻寡糖、海藻多酚、氯化钠以及抗菌剂能够有效抑制细菌和真菌,保护受损肌肤,此外,PH调节剂、皮肤粘合剂和润肤保湿剂能够帮助肌肤恢复最佳pH值,同时对肌肤进行保湿润滑,卡波姆能够对上述原料进行凝胶、增稠。这些原辅料混合后在伤口表面可以形成保护层利于屏障受损皮肤与粘膜的损伤修复与护理。
该海藻纤维功能性敷料的原料中的卡拉胶寡糖还具有抗凝血作用,能够帮助受损肌肤的伤口愈合。同时卡拉胶寡糖对辐射损伤有明显的防护作用,并且具有很强的清除超氧阴离子自由基以及羟自由基的活性,并且具有还原能力,而褐藻寡糖、海藻多酚和原花青素都具有抗氧化活性,卡拉胶寡糖与褐藻寡糖、海藻多酚和原花青素相互配合,加强了抗氧化活性的能力,进而能够对受损皮肤起到修护作用。此外,褐藻寡糖、海藻多酚、原花青素和氯化钠还具有抑菌活性,能够防止受损肌肤受到细菌及真菌的损害,保护受损肌肤。原料中的PH调节剂能够调节海藻纤维功能性敷料和皮肤的pH值,使肌肤保持最佳状态,而皮肤粘合剂与卡波姆配合能够使海藻纤维功能性敷料呈胶液状态,同时能够帮助受损肌肤伤口愈合,润肤保湿剂能够保持肌肤水分,进而保持伤口的湿润环境。运用湿性愈合理论治疗创伤面能减轻疼痛和避免干痂形成,并形成湿润的愈合环境。大大缩短了伤口愈合的时间,降低了伤口污染和感染的发生,减少了护理人员工作量,显著提高了临床经济效益。本发明实施例中选用的原料均为安全无毒副作用的材料,更安全。本发明运用湿性愈合理论治疗创伤面能减轻疼痛和避免干痂形成,并形成湿润的愈合环境。大大缩短了伤口愈合的时间,降低了伤口污染和感染的发生,减少了护理人员工作量,显著提高了临床经济效益。
应注意,本发明实施例中选用的原料均为非动物源成分,能够避免选用动物源原料产生的过敏、相容性差、排异性高等问题,本发明实施例选用的原料安全、无副作用,例如,卡拉胶寡糖是由卡拉胶降解得到的,褐藻寡糖、海藻多酚和原花青素都是从植物中提取,植物源的原料人体创面的相容性更高,排异性低,进而不容易引起过敏的现象,本发明实施例制得的海藻纤维功能性敷料不仅可用于外敷,还可以内服。该海藻纤维功能性敷料的制备方法简单,具体步骤如下:
S1、将配方量的皮肤粘合剂溶于注射用水中,制成溶液,用PH调节剂调节PH值,至5.5-7.5,放置3~4h,再用过滤膜过滤制得胶液备用;
S2、将配方量的卡拉胶寡糖、褐藻寡糖、海藻多酚、原花青素和润肤保湿剂溶于少量注射用水中,加配方量的氯化钠,然后加入体积量的0.5%的针剂用活性炭溶解循环30min制得修复液;
S3、将S2的修复液过滤至澄清后与S1中的胶液混合,加注射用水调节卡拉胶寡糖、褐藻寡糖、海藻多酚、原花青素、润肤保湿剂、皮肤粘合剂和PH调节剂的含量在配方范围内,并用氯化钠调节等渗,制得海藻纤维功能性敷料;
S4、对S3中的海藻纤维功能性敷料进行灭菌。
本实施例提供的海藻纤维功能性敷料的制备方法简单,操作容易,易实现。
此外,本发明实施例提供了一种海藻纤维功能性敷料贴,其包括敷料面层,敷料面层上均匀吸附有上述海藻纤维功能性敷料。敷料面层的材料可选自无纺布、生物纤维材料、果胶纤维布、棉布和蚕丝中的任意一种。
其中,生物纤维材料是有木醋杆菌自然发酵制成的纤维体。具有类似皮肤的功能,能透氧隔离细菌,能使用于烧烫伤的披覆物,是经由严谨的发酵工程,孕育衍生出来的纳米级有机纤维。
生物纤维材料的特性如下:有机纤维制成的天然纤维是自然界中最微小的有机纤维,纤维直径约为0.05~0.08微米,同时呈现3D立体交错结构,能让空气通过,柔软同时具有绝佳韧性。它有极强的吸水性能和极强的排油去污能力,无论被任何信用油或工业用油所污染,都可以轻易地在清水中洗去,无需清洁剂,且自身具有不沾油污的特性。利用生物纤维材料制成的面膜质地非常柔软,弹性好,韧性强,无刺激无异味,不易生长细菌、不含荧光物质,容易清洗,是纯天然健康环保用品。由于生物纤维材料具有不被人体排斥的特性,因此,在医学界被用来作为心血管修复与人造皮肤使用。
由于生物纤维面膜具超强的亲肤性,同时又具有能贴入皱纹与皮丘深处的包覆能力,因此较一般布织面膜更提升敷面效果,并可贴紧肌肤,不会出现一般面膜脱落的现象。本实施例中优选采用生物纤维材料作为敷料面层。
在实际生产和应用中,可将该海藻纤维功能性敷料贴裁剪成任意的形状,以贴合不同形状的创面。骶椎形、关节状、面膜状、蝴蝶及泪滴状、锯齿状。海藻纤维功能性敷料贴规格有多种选择,例如:5g、10g、15g、20g、25g、30g、35g、50g。
本实施例提供的海藻纤维功能性敷料贴为一次性使用的外用非无菌医用敷料,其外敷于浅表创伤面25-30分钟后去除,预期使用时间在24小时以内,对面部激光、光子嫩肤、微晶磨削、果酸活肤术等微创术后的色素沉着与疤痕形成,可促进皮肤对营养物质的吸收,缩短病程以及对人体浅表创面、皮炎湿疹、日光性皮炎、过敏性皮炎、激素依赖性皮炎等造成屏障受损皮肤与粘膜的损伤具有修复与护理的作用,根据《医疗器械分类规则(局令第15号)》第六条和医疗器械分类判定表进行分类判定为Ⅱ类医疗器械项下的6864医用卫生材料及敷料。
此外,本发明实施例还提供了上述海藻纤维功能性敷料在修复和愈合皮肤损伤中的应用。具体的,该海藻纤维功能性敷料能够适用于人体浅表创面、皮炎湿疹、日光性皮炎、过敏性皮炎、激素依赖性皮炎、褥疮、糖尿病足、脓肿、溃疡等,对屏障受损皮肤与粘膜的损伤具有修复与护理的作用;对面部激光术、光子嫩肤、微晶磨削、果酸活肤术等微创术后的色素沉着与疤痕形成、轻中度痤疮等皮肤炎症后期继发性皮损,如红斑、色素沉着斑、干燥脱屑、微小疤痕、肿胀、薄痂皮,具有抗氧化、清除自由基、改善皮肤过敏、美化肌肤、防止过度日晒所导致的皮肤损伤、促进皮肤对营养物质的吸收,同时有利于保持皮肤弹性的作用。
下面结合具体实施例对本发明的配方进行阐述。
实施例一:
海藻纤维功能性敷料的原料用量如下:卡拉胶寡糖1%、褐藻寡糖1.8%、海藻多酚0.6%、原花青素1%、氯化钠0.07%、卡波姆0.5%、PH调节剂0.06%、皮肤粘合剂0.6%、润肤保湿剂0.2%、生物肽0.15%、注射用水加至100%。其中,PH调节剂为柠檬酸;皮肤粘合剂为羧甲基纤维素钠;润肤保湿剂为丙三醇;抗菌剂为生物肽。
海藻纤维功能性敷料的制备方法:将上述原料按照配比溶解于注射用水中,搅拌均匀。
海藻纤维功能性敷料贴的制备方法:将果胶纤维布材料制成的敷料面层浸泡于本实施例提供的海藻纤维功能性敷料中,使敷料面层上均匀吸附该海藻纤维功能性敷料,制得海藻纤维功能性敷料贴。
实施例二
海藻纤维功能性敷料的原料用量如下:卡拉胶寡糖1.5%、褐藻寡糖2.5%、海藻多酚0.5%、原花青素1.2%、氯化钠0.07%、卡波姆1.5%、PH调节剂0.05%、皮肤粘合剂1.3%、润肤保湿剂0.1%、抗菌剂0.04%、异抗坏血酸0.25%、注射用水加至100%。其中:PH调节剂为柠檬酸;皮肤粘合剂为羧甲基纤维素钠;润肤保湿剂为丙三醇;抗菌剂为壳寡糖。
海藻纤维功能性敷料贴的制备方法:本实施例中,海藻纤维功能性敷料贴的制备方法与实施例一相同,不同之处在于,本实施例中海藻纤维功能性敷料贴的敷料面层是由无纺布材料制成的。
实施例三
海藻纤维功能性敷料的原料用量如下:卡拉胶寡糖1.1%、褐藻寡糖2%、海藻多酚1%、原花青素1.9%、氯化钠0.07%、卡波姆1%、PH调节剂0.04%、皮肤粘合剂0.5%、润肤保湿剂0.05%、抗菌剂0.19%、注射用水加至100%。其中,PH调节剂为柠檬酸0.02%和柠檬酸钠0.02%;皮肤粘合剂为羧甲基纤维素钠;润肤保湿剂为丙三醇;抗菌剂为十三肽。
海藻纤维功能性敷料贴的制备方法:本实施例中,海藻纤维功能性敷料贴的制备方法与实施例一相同,不同之处在于,本实施例中海藻纤维功能性敷料贴的敷料面层是由生物纤维材料制成的。
实施例四
海藻纤维功能性敷料的原料用量如下:卡拉胶寡糖0.5%、褐藻寡糖1.5%、海藻多酚1.5%、原花青素0.5%、氯化钠0.05%、卡波姆0.7%、PH调节剂0.01%、皮肤粘合剂2%、润肤保湿剂0.01%、抗菌剂0.2%、注射用水加至100%。其中,PH调节剂为磷酸;皮肤粘合剂为羧甲基纤维素钠1%和α-氰基丙烯酸酯1%;润肤保湿剂为丙三醇;抗菌剂为生物肽0.1%和十三肽0.1%。
海藻纤维功能性敷料贴的制备方法:本实施例中,海藻纤维功能性敷料贴的制备方法与实施例一相同,不同之处在于,本实施例中海藻纤维功能性敷料贴的敷料面层是由蚕丝材料制成的。
实施例五
海藻纤维功能性敷料的原料用量如下:卡拉胶寡糖2%、褐藻寡糖3%、海藻多酚1%、原花青素2.5%、氯化钠0.2%、卡波姆0.8%、PH调节剂0.1%、皮肤粘合剂1%、润肤保湿剂0.15%、抗菌剂0.15%、异抗坏血酸0.3%、注射用水加至100%。其中,PH调节剂为柠檬酸0.05%、磷酸0.01%、磷酸钠0.02%和柠檬酸钠0.02%;皮肤粘合剂为α-氰基丙烯酸酯;润肤保湿剂为三乙醇胺;抗菌剂为生物肽0.05%、壳寡糖0.05%和十三肽0.05%。
实施例六
海藻纤维功能性敷料的原料用量如下:卡拉胶寡糖1.2%、褐藻寡糖2%、海藻多酚0.8%、原花青素2%、氯化钠0.1%、卡波姆0.6%、PH调节剂0.08%、皮肤粘合剂1.5%、润肤保湿剂0.1%、抗菌剂0.1%、异抗坏血酸0.2%、注射用水加至100%。其中,PH调节剂为柠檬酸0.05%、磷酸0.01%、和柠檬酸钠0.02%;皮肤粘合剂为α-氰基丙烯酸酯;润肤保湿剂为三乙醇胺;抗菌剂为生物肽。
接下来先对本实施例中的海藻纤维功能性敷料进行检测并得出检测结果如表1:
表1.检测结果
其次对本实施例中提供的海藻纤维功能性敷料贴进行说明:
1、使用方法:外用。清洁患处皮肤,取海藻皮肤修复贴外敷患处,轻压无纺布使其贴紧,每次25-30分钟,每天一次,连续使用一周,第二周使用2-3次,两周为一疗程。
2、性能指标
2.1外观:湿润的纤维面膜或胶状成形贴膜。
2.2pH值:5.5-7.5。
2.3重金属:不得过百万分之六十。
2.4菌落总数:≤1000CFU/g
2.5霉菌:≤100CFU/g
2.6绿脓杆菌:不得检出。
2.7急性全身毒性:无急性全身毒性。
2.8刺激:无反应。
3试验方法
3.1外观
取3片在正常光照下目测,应符合2.1的规定。
3.2pH值
将贴膜中的水或粘稠液挤出,根据(《中国药典》2015年版四部通则0631)依法检验,控制范围应符合2.2的规定。
3.3重金属
根据(《中国药典》2015年版四部通则0821第一法)依法检验,仲裁法根据(《中国药典》2015年版四部通则2321)依法检验,控制范围应符合2.3的规定。
3.4菌落总数
根据(《中国药典》2015年版四部通则1105)依法检查,符合2.4的规定。
3.5霉菌
根据(《中国药典》2015年版四部通则1105)依法检查,符合2.5的规定。
3.6绿脓杆菌
根据(《中国药典》2015年版四部通则1105)依法检查,符合2.6的规定。
3.7急性全身毒性试验
按照0.1g/mL的比例,(37±1)℃条件下浸提(72±2)h,按照GB/T 16886.11—2011中第五章规定试验方法,采用A.2皮肤接触途径进行试验,结果应符合2.7的要求。
3.8刺激
按照0.1g/mL的比例,(37±1)℃条件下浸提(72±2)h,按照GB/T 16886.10-2005中附录B.2规定进行试验,结果应符合2.8的要求。
4、对比试验:与同类产品的比较相同性
综上所述,皮肤修护敷料与海藻纤维功能性敷料在性能要求、预期用途、使用方法、生产工艺相同且皮肤修护敷料已上市2年,从未发生过任何临床可疑不良事件,一些临床使用数据在“中国知网”可查询到。在国家食品药品监督管理局官方数据信息上也可以查到很多同类产品的相关信息。两个产品的对比说明表可参见表2。
表2.产品对比说明表
以下对上述两种产品的对比实验进行说明,但本发明的应用不限于此。
应用例
选取微创术后、皮炎湿疹、痤疮、过敏性皮炎患者共100例,年龄13~37岁,其中;微创术后患者25例,含女性20例,男性5例;皮炎湿疹患者40例,含女性30例,男性10例;痤疮患者15例,含女性8例,男性7例;过敏性皮炎患者20例,含女性15例,男性5例。对此100例患者采取如下治疗方案:清洁患处皮肤,取海藻纤维功能性敷料外敷患处,每次25-30分钟,每天一次,连续使用一周,第二周使用2-3次,两周为一疗程。
疗效评价标准包括:
(1)治愈:创口完全消失,无细菌感染和疤痕产生;
(2)有效:创口明显消除,无细菌感染,疤痕产生但颜色浅;
(3)无效:创口无明显变化。
临床应用实验结果参见表3:
表3.敷用海藻纤维功能性敷料的临床应用实验结果
| 病情 | 总人数 | 治愈 | 有效 | 无效 | 有效率 |
| 微创术后 | 25人 | 20 | 5 | 0 | 100% |
| 皮炎湿疹 | 40人 | 28 | 12 | 0 | 100% |
| 痤疮 | 15人 | 13 | 2 | 0 | 100% |
| 过敏性皮炎 | 20人 | 13 | 7 | 0 | 100% |
由上表应用实验结果可知,本发明实施例提供的海藻纤维功能性敷料针对微创术后、皮炎湿疹、痤疮、过敏性皮炎等创面肌肤均有具有显著的疗效。
此外,为进一步说明本发明实施例提供的海藻纤维功能性敷料的疗效,还进行了大量的临床对比实验,下面以现有的常用的皮肤修护敷料为例进行说明,但对比说明不限于此。该皮肤修护敷料的具体成分和工作原理可参见上述表2。
对照实验例
选取微创术后、皮炎湿疹、痤疮、过敏性皮炎患者共100例,年龄16~33岁,其中;微创术后患者35例,含女性28例,男性7例;皮炎湿疹患者28例,含女性20例,男性8例;痤疮患者25例,含女性8例,男性17例;过敏性皮炎患者12例,含女性6例,男性6例。对此100例患者采取如下治疗方案:清洁患处皮肤,取皮肤修复敷料外敷患处,每次25-30分钟,每天一次,连续使用一周,第二周使用2-3次,两周为一疗程。
疗效评价标准包括:
(1)治愈:创口完全消失,无细菌感染和疤痕产生;
(2)有效:创口明显消除,无细菌感染,疤痕产生但颜色浅;
(3)无效:创口无明显变化。
临床应用实验结果参见表4:
表4.敷用皮肤修复敷料的临床应用实验结果
| 病情 | 总人数 | 治愈 | 有效 | 无效 | 有效率 |
| 微创术后 | 35人 | 10 | 20 | 5 | 85.7% |
| 皮炎湿疹 | 28人 | 10 | 14 | 4 | 85.7% |
| 痤疮 | 25人 | 15 | 3 | 7 | 72% |
| 过敏性皮炎 | 12人 | 1 | 3 | 8 | 33.3% |
经对照实验例可以看出,本发明实施例提供的海藻纤维功能性敷料针对微创术后、皮炎湿疹、痤疮、过敏性皮炎均有良好的治疗效果,有效率达到100%。
以上所描述的实施例是本发明一部分实施例,而不是全部的实施例。本发明的实施例的详细描述并非旨在限制要求保护的本发明的范围,而是仅仅表示本发明的选定实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
Claims (5)
1.一种海藻纤维功能性敷料,适用于微创手术后的创面护理,其特征在于,其原料按质量百分数计包括:
所述PH调节剂包括柠檬酸、磷酸、磷酸钠和柠檬酸钠中的至少一种;
所述皮肤粘合剂包括羧甲基纤维素钠和α-氰基丙烯酸酯中的至少一种;
所述润肤保湿剂为三乙醇胺或丙三醇;
所述抗菌剂包括生物肽、壳寡糖和十三肽中的至少一种。
2.根据权利要求1所述的海藻纤维功能性敷料,其特征在于,所述原料按质量百分数计包括:
3.一种海藻纤维功能性敷料贴,其特征在于,其包括敷料面层,所述敷料面层上均匀吸附有如权利要求1~2任一项所述的海藻纤维功能性敷料。
4.根据权利要求3所述的海藻纤维功能性敷料贴,其特征在于,所述敷料面层的材料选自无纺布、生物纤维材料、果胶纤维布、棉布和蚕丝中的任意一种。
5.如权利要求1~2任一项所述的海藻纤维功能性敷料在修复和愈合皮肤损伤的材料中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710066389.3A CN106822988B (zh) | 2017-02-08 | 2017-02-08 | 海藻纤维功能性敷料及其应用、海藻纤维功能性敷料贴 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710066389.3A CN106822988B (zh) | 2017-02-08 | 2017-02-08 | 海藻纤维功能性敷料及其应用、海藻纤维功能性敷料贴 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106822988A CN106822988A (zh) | 2017-06-13 |
| CN106822988B true CN106822988B (zh) | 2019-12-31 |
Family
ID=59121406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710066389.3A Active CN106822988B (zh) | 2017-02-08 | 2017-02-08 | 海藻纤维功能性敷料及其应用、海藻纤维功能性敷料贴 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106822988B (zh) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109106979A (zh) * | 2018-09-11 | 2019-01-01 | 吉林省蓝鼎陆和科技有限公司 | 一种十三肽抗菌敷料及其制备方法 |
| CN110882176A (zh) * | 2018-09-11 | 2020-03-17 | 吉林省蓝鼎陆和科技有限公司 | 一种以opc为载体的十三肽修复保湿面膜及其制作方法 |
| CN108852900B (zh) * | 2018-09-11 | 2021-12-14 | 吉林省蓝鼎陆和科技有限公司 | 一种含有十三肽的抗菌面膜及其制作方法 |
| CN108852944A (zh) * | 2018-09-11 | 2018-11-23 | 吉林省蓝鼎陆和科技有限公司 | 一种以opc为载体的十三肽抗菌修复乳液及其制备方法 |
| CN109619163A (zh) * | 2018-12-01 | 2019-04-16 | 浙江海洋大学 | 一种海藻多酚-卡拉胶寡糖复合物的制作方法 |
| CN110935056A (zh) * | 2019-12-30 | 2020-03-31 | 山东星之诚生物科技有限公司 | 一种高吸湿性藻酸盐敷料制备方法 |
| CN111068097B (zh) * | 2020-01-08 | 2021-12-07 | 优锐医药科技(上海)有限公司 | 一种杀菌抗炎创面修复敷料及其制备方法 |
| CN111719221A (zh) * | 2020-07-06 | 2020-09-29 | 温州大学 | 一种糖尿病足专用高透气纱布的制备方法 |
| CN113318263B (zh) * | 2021-08-02 | 2021-11-09 | 山东省千佛山医院 | 一种抗菌型敷料及其制备方法 |
| CN115607725A (zh) * | 2021-12-31 | 2023-01-17 | 上海炫鑫医药科技有限公司 | 一种强抗菌性的医用敷料及其制备方法 |
| CN114832139A (zh) * | 2022-05-17 | 2022-08-02 | 江西昂生生物科技有限公司 | 一种创面修复功能性敷料及其制备方法和用途 |
| CN117427201B (zh) * | 2023-12-20 | 2024-03-15 | 辽宁帝东医药生物工程有限公司 | 一种抑菌促愈合伤口敷料 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101279990A (zh) * | 2008-05-05 | 2008-10-08 | 中国海洋大学 | iota-卡拉胶偶数寡糖单体及其制备方法 |
| CN104622897A (zh) * | 2015-03-04 | 2015-05-20 | 中英阿诺康(宁夏)生物科技有限公司 | 一种治疗皮肤病的护肤液及其制备方法 |
| CN104994843A (zh) * | 2013-02-13 | 2015-10-21 | 东亚制药株式会社 | 用于创伤愈合的成膜药物组合物和用于制备其的方法 |
| CN105536042A (zh) * | 2016-01-26 | 2016-05-04 | 依莱恩(上海)实业有限公司 | 水凝胶伤口敷料及其制备方法与应用 |
| WO2016199905A1 (ja) * | 2015-06-12 | 2016-12-15 | Jfeミネラル株式会社 | 皮膚創傷または皮膚荒れ治療剤 |
-
2017
- 2017-02-08 CN CN201710066389.3A patent/CN106822988B/zh active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101279990A (zh) * | 2008-05-05 | 2008-10-08 | 中国海洋大学 | iota-卡拉胶偶数寡糖单体及其制备方法 |
| CN104994843A (zh) * | 2013-02-13 | 2015-10-21 | 东亚制药株式会社 | 用于创伤愈合的成膜药物组合物和用于制备其的方法 |
| CN104622897A (zh) * | 2015-03-04 | 2015-05-20 | 中英阿诺康(宁夏)生物科技有限公司 | 一种治疗皮肤病的护肤液及其制备方法 |
| WO2016199905A1 (ja) * | 2015-06-12 | 2016-12-15 | Jfeミネラル株式会社 | 皮膚創傷または皮膚荒れ治療剤 |
| CN105536042A (zh) * | 2016-01-26 | 2016-05-04 | 依莱恩(上海)实业有限公司 | 水凝胶伤口敷料及其制备方法与应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106822988A (zh) | 2017-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106822988B (zh) | 海藻纤维功能性敷料及其应用、海藻纤维功能性敷料贴 | |
| CN103083713B (zh) | 一种无菌聚合创面覆盖物敷料 | |
| DE602004002717T2 (de) | Blattförmige Wundauflage aus mikrobieller Zellulose, enthaltend PHMB, für chronische Wunden | |
| CN105168038B (zh) | 金花葵花朵泥面膜及其制备方法 | |
| CN102138872B (zh) | 壳聚糖护肤液及其制备方法 | |
| CN111632075B (zh) | 一种促进皮肤创面愈合的外泌体制剂及其制备方法 | |
| CN105107008A (zh) | 一种羟丁基壳聚糖/氧化海藻酸钠/纳米银复合水凝胶敷料贴 | |
| CN110507845A (zh) | 生物复合透气敷料及其制备方法 | |
| CN108686255B (zh) | 一种预防疤痕形成的生物敷料及其制备方法 | |
| CN111616992B (zh) | 一种皮肤屏障修护复合物、肌底液及其制备方法 | |
| CN113975197A (zh) | 一种含有聚谷氨酸钠的组合物及其应用的敷料 | |
| CN107296764A (zh) | 膏霜及其制备方法 | |
| Gokarneshan | Application of natural polymers and herbal extracts in wound management | |
| CN117731829A (zh) | 一种医用凝胶敷料及其制备方法 | |
| Fletes-Vargas et al. | Natural hydrogels as wound dressing for skin wound-healing applications | |
| US11058712B2 (en) | Film for topical application in the treatment of skin lesions and method of obtaining and applying same | |
| Khorasani et al. | The effects of aloe vera cream on split-thickness skin graft donor site management: a randomized, blinded, placebo-controlled study | |
| CN111643722A (zh) | 一种含艾考糊精的透明质酸钠贴敷料 | |
| Morgan | Alginate dressings: part 1: historical aspects | |
| WO2023187632A1 (en) | Composition, application of the composition, cosmetic preparation hydrogel bio-mask in the form of a compress, method of manufacturing the preparation | |
| CN111714681A (zh) | 一种医用贴敷料及其制备方法 | |
| CN114984294A (zh) | 一种敷料及其制备方法 | |
| CN110090224B (zh) | 促进伤口愈合的胶体敷料 | |
| CN109010907B (zh) | 一种功能性护创液体敷料及其制备方法 | |
| CN112957519A (zh) | 用于制备促进创口愈合的水凝胶的组合物、水凝胶及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |